Boomer Esiason’s commitment to enhancing the quality of life for cystic fibrosis sufferers has become the stuff of legend. Add Teaser here Read More »
Novartis today announced that the US Food and Drug Administration (FDA) has approved Gilenya® (fingolimod) for the treatment of children and adolescents 10 to less than 18 years of age with relapsing forms of multiple sclerosis, making it the first disease-modifying therapy indicated for these patients2. Read More »
AstraZeneca and MedImmune, its global biologics research and development arm, today announced top-line results from the GALATHEA Phase III trial for Fasenra (benralizumab) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD). Read More »
The fundamental issues with prescription drug affordability are the high prices set by and marketing practices of pharmaceutical manufacturers, so we welcome the Administration’s focus on reducing drug costs. Read More »
“The American Diabetes Association’s new white paper on insulin prices confirms that drugmakers set, and continue to raise, prices. Read More »
Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Valeant Pharmaceuticals International (NYSE/TSX: VRX), today announced the launch of LUMIFY™ (brimonidine tartrate ophthalmic solution 0.025%), the first and only over-the-counter (OTC) eye drop developed with low-dose brimonidine tartrate for the treatment of eye redness. Read More »
Taxes are lower, ISIS is on the run, and the regulatory agencies are in a ceasefire with the US economy. Read More »
The Rite Aid Foundation recently announced the rollout of its KidCents Safe Medication Disposal Program, which will focus on reducing drug accessibility, medication misuse and accidental poisoning of children and adolescents. Read More »
The makers of a new, opioid-free inhalable pain reliever have launched a campaign to market the drug to more than 9,000 women’s healthcare providers across the U.S. this fall. Read More »
Novartis recently announced that the U.S. Food and Drug Administration (FDA) approved Kymriah suspension for intravenous infusion for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. Read More »
Merck and researchers from the Clinical Trial Service Unit at the University of Oxford recently announced positive results for the REVEAL Study. Read More »
Coherus BioSciences Inc. of Redwood City, California recently announced initial results from several current clinical pharmacokinetic bioequivalence (PK/BE) studies comparing two products, both developed for the purpose of addressing certain chronic arthritic and skin conditions. Read More »
Endo International plc of Dublin, Ireland recently launched shipping operations for its generic Sabril (vigabatrin for oral solution USP, 500 mg) product via Par Pharmaceutical, following final approval of its Abbreviated New Drug Application (ANDA). Read More »
Accorda Therapeutics Inc. recently announced that the U.S. Food and Drug Administration (FDA) provided a Refusal to File (RTF) letter regarding the company’s New Drug Application (NDA) for Inbrija, an investigational treatment for symptoms of OFF periods in people with Parkinson’s disease taking a carbidopa/levodopa regimen. Read More »
Newly compiled data from the Blue Cross Blue Shield Association indicates that the nation — particularly the state of Massachusetts — has substantially lowered the number of outpatient prescriptions for antibiotics, association sources announced recently from Boston. Read More »
Biologics Inc., an oncology pharmacy services company under the McKesson Specialty Health umbrella, recently announced that Pfizer selected it to distribute Besponsa, a new IV therapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Read More »
Amgen and Humana Inc. will collaborate on finding opportunities to improve health outcomes by analyzing the real-world health care experiences of Humana's 13 million members. Read More »
Takeda Pharmaceuticals Co. Limited recently announced that it will collaborate with Stanford University to form the Stanford Alliance for Innovative Medicines (Stanford AIM) to transform novel Stanford research into next-generation treatments for diseases. Read More »
Express Scripts, one of the largest pharmacy benefit managers (PBMs) in the country, has announced the expansion of a pilot program that limits opioid prescriptions to seven days without prior authorization. Read More »
A trial treatment for peanut allergy has attracted attention in the media, with a recent Washington state publication highlighting California-based Aimmune Therapeutics Inc.’s “AR101” as a potential immunotherapy with the ability to impact allergen-specific T cells. Read More »
Alerts Sign-up
